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ABSTRACT
While many efforts have been made to pave the way toward human space 
colonization, little consideration has been given to the methods of protecting 
spacefarers against harsh cosmic and local radioactive environments and the high 
costs associated with protection from the deleterious physiological effects of exposure 
to high-Linear energy transfer (high-LET) radiation. Herein, we lay the foundations 
of a roadmap toward enhancing human radioresistance for the purposes of deep 
space colonization and exploration. We outline future research directions toward 
the goal of enhancing human radioresistance, including upregulation of endogenous 
repair and radioprotective mechanisms, possible leeways into gene therapy in order to 
enhance radioresistance via the translation of exogenous and engineered DNA repair 
and radioprotective mechanisms, the substitution of organic molecules with fortified 
isoforms, and methods of slowing metabolic activity while preserving cognitive 
function. We conclude by presenting the known associations between radioresistance 
and longevity, and articulating the position that enhancing human radioresistance is 
likely to extend the healthspan of human spacefarers as well.
INTRODUCTION
Cosmic radiation and microgravity represent two 
major environmental contributors to human health risks 
and substantially limit the prospects of long spaceflights 
[1]. The necessity to protect the human body from the 
deleterious effects of cosmic radiation has been largely 
overlooked. For deep space exploration missions, 
including the mission to Mars, exposure to radiation 
represents one of several unacceptable risk categories [2, 
3], since cumulative doses received by astronauts would 
greatly exceed the human dose limits established within 
the current NASA radiological protection system [4]. A 
3% exposure-induced death risk limit, mostly from fatal 
radiation-induced cancer, is set according to this paradigm 
[3]. Implementation of additional protection systems 
including biotechnological concepts described here may 
help resolve this issue and make it possible to begin the 
era of deep space manned missions.
The main components of space radiation are 
solar particle events (SPE), geomagnetically trapped 
radiation and galactic cosmic radiation (GCR) [5]. The 
contribution of the first two to the total dose absorbed by 
astronauts would obviously be negligible on long-duration 
missions away from Earth and the Sun. Consequently, 
GCR consisting mainly of highly-energetic particles 
(reviewed below) would be the primary type of radiation 
encountered by humans under this scenario ([2, 3, 6]). It 
has been estimated that a return trip to Mars could subject 
astronauts to radiation doses of 660 mSv [7]. Although 
great uncertainties exist with respect to health (cancer) risk 
estimates from exposure to cosmic radiation [7, 8], this 
dose alone represents more than half of the total NASA 
astronaut career limit of 800-1200 mSv [9, 10]. Obviously, 
longer missions would not be acceptable for human 
in terms of cancer risk under current radioprotection 
guidelines. Due to very high energies of charged particles 
of GCR they easily penetrate passive shielding materials. 
Although active shielding technologies are also currently 
being explored, there has been no substantial progress 
in significantly reducing fluxes of GCR down to levels 
suitable for long-duration human space missions [11, 12]. 
It is therefore important to explore various prospects of 
improving human radioresistance using recent advances 
in biotechnology. These would include the possibility of 
genetic modifications to humans utilizing breakthrough 
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technologies in gene editing in combination with the 
current knowledge of molecular pathways counteracting 
radiation-induced DNA damage, as well as other 
possible therapies, such as regenerative medicine, low-
dose radioadaptation, the use of deuterated organic 
compounds, hypostasis (considerable slowdown of all 
the vital processes in the body) or a combination thereof. 
Finally, the primary focus of this concept review is the 
radioprotection against DNA damage driven health risks, 
mainly cancer. Some of the ideas in this review could 
potentially be utilized for alleviating other detrimental 
effects of long space travel, such as muscle and bone 
deterioration.
In principle, ionizing radiation interacts along 
charged particle tracks with biological molecules such as 
DNA. The process is largely stochastic, and can damage 
DNA via direct interactions (e.g. ionization and excitation) 
or via indirect interactions such as through the production 
of reactive oxygen species (ROS) as a result of radiolysis 
of water molecules [13].
Radioresistance denotes the capacity for organisms 
to protect against, repair and remove molecular, cellular 
and tissue damage caused by ionizing radiation. It is 
a quality that varies greatly in terms of effectiveness 
between different organisms. For instance, it is well-
known that certain organisms are remarkably resistant 
to the damaging effects of radiation. The bacterium 
Deinococcus radiodurans, for instance, possess error-free 
DNA repair mechanisms and can withstand doses as high 
as 7 kGy [14]. Similarly, tardigrades can withstand doses 
as high as 5 kGy, though doses exceeding 1 kGy render 
them sterile. Initially, the remarkable radioresistance 
of tardigrades was thought to be the result of their 
anhydrobiotic (i.e. dehydrated) state reducing the effective 
concentration of hydrolyzable water. However, subsequent 
studies have found that hydrated tardigrades were more 
radioresistant to both gamma-rays and heavy ions than 
anhydrobiotic specimens (the median lethal dose being 
5 kGy for gamma-rays and 6.2 kGy for heavy ions in 
hydrated animals compared to 4.4 kGy for gamma-rays 
and 5.2 kGy for heavy ions an anhydrobiotic specimens) 
[15]. By comparison, the human median lethal dose is 
around 0.004 kGy.
Currently, the European Space Agency ESA is 
conducting intensive research on the possibility of the 
remote space missions. Given that the flight will take 
place mainly under the control of automatic systems, 
where the participation of the astronauts is almost not 
necessary, the space crew will be virtually imprisoned 
for many months without having any work to do. Such 
situations may be dangerous, especially for the astronauts 
themselves. Therefore, the ESA believes that it would 
be wiser to immerse people into hibernation. Currently 
ESA has started the project “Aurora”, where the option of 
crew hibernation is considered. The project team intends 
to engage the biological mechanisms that will allow the 
crew to sleep and thereby reduce the metabolism of the 
organism to the absolute minimum [16].
It is worth emphasizing that the idea of possible 
hibernation during the long space missions was also 
explored in the USSR in 1969, but, unfortunately, after 
the death of the father of Soviet cosmic program Sergei 
Korolev the Soviet manned “Mars project” was closed, 
and all the work related to its implementation was 
terminated. The results of these studies included data on 
the hyperresistance to various damaging factors including 
lethal doses of ionizing radiation, long-term lethal 
overloads and hypobaric hypoxia in mice [17].
SPACE RADIATION ENVIRONMENT
Beyond the reach of the Earth’s magnetosphere, 
cosmic rays refer to a heterogenous pool of ionizing 
radiation with a diverse range of energies and charges. 
They can be subdivided into two main types, including 
galactic cosmic rays (GCRs) consisting of a constant 
flux of high energy particles originating in cataclysmic 
astronomical events outside the solar system, and solar 
energetic particles produced by the Sun ([18]). GCRs 
mainly consist of approximately 85% high-energy protons, 
12% alpha-particles, and 2% electrons. Importantly, 
there is a small (1%), but biologically relevant presence 
of high charge (Z) and energy (E) (HZE) nuclei [19]. 
Due to their high linear energy transfer (LET), this HZE 
component of GCRs represents a significant danger, and 
they are predicted to account for most of the biological 
consequences of cosmic radiation exposure [20, 21]. It has 
long been recognized that HZE ions have a higher relative 
biological effectiveness (RBE) compared to gamma-rays 
and must pose a significant cancer risk to humans in space 
[22].
In addition to GCRs, astronauts in space are exposed 
to solar energetic particles (SPEs), emitted by the Sun 
produced either via solar-flares or coronal mass ejections. 
SPEs are unpredictable and are largely comprised of low 
to medium energy protons.
Interaction of this primary cosmic radiation with 
the spacecraft shielding can create secondary radiation, 
mainly represented by neutrons, electrons, mesons and 
gamma-rays. This secondary radiation is thought to 
contribute to the overall radiation exposure as well [18, 
22–24]. Recently, using NASA’s models of risks and 
uncertainties, predictions were made for cancer and 
circulatory diseases related to space exploration missions 
to Mars near the solar minimum [2, 3]. It was estimated 
that radiation induced mortality and morbidity could 
exceed 5% and 10% with upper 95% confidence interval 
near 10% and 20% respectively for a Mars mission (Figure 
1). Most recent estimates of cancer risks associated with 
Mars mission carried out using non-targeted effects model, 
thought to be more accurate at low-dose exposures, 
resulted in higher than previously assumed risks [25].
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MOLECULAR AND CELLULAR 
EFFECTS OF COSMIC RAYS AND 
MECHANISMS OF PROTECTION
Ionizing radiation’s ability to induce genetic 
mutations had been established [26] well before the 
elucidation of the DNA double helix structure by Watson 
and Crick, or even before the Hershey-Chase experiment, 
which demonstrated that DNA is indeed the genetic 
material. The effects of ionizing radiation on DNA tend 
to be more serious than other biological macromolecules, 
with delayed systemic health effects being the outcome of 
DNA and chromosomal damage [27, 28].
The majority of cellular DNA lesions caused by 
ionizing radiation differ significantly from those caused 
by endogenous sources in their physical and chemical 
properties [29]. The most important features of radiation-
induced DNA lesions are their complexity and clustering 
[30]. The radiation-induced DNA double-strand breaks 
(DSBs) tend to be the most crucial for the cell fate and 
can thus be considered to be a basic trigger for the cellular 
response and adaptation to the radiation exposure [31, 
32]. Because eukaryotic cells primarily repair DSBs via 
the method of non-homologous end joining or allelic 
recombination (see below), there exists an unfortunate 
tendency to lose genetic information by means of loss 
of heterozygosity and deletions, as well as genetic 
rearrangements [33]. This can lead to serious cytogenetic 
lesions and cell death, or transformation and oncogenicity 
via the inactivation of tumor suppressor genes or the 
activation of certain oncogenes [34–36].
LET denotes the amount of energy released by 
a particle or a photon over the length of its trajectory 
(typically in a unit of energy per unit length, i.e. keV/μm). 
As discussed above, Galactic Cosmic Rays are comprised 
of high charge and energy particles (referred to as HZE). 
The considerable speed of these particles makes them 
essentially electron-free (in other words they carry a high 
positive charge) and consequently, due to their Coulombic 
interactions with matter, they tend to decelerate on a 
Figure 1: Major sources of space radiation. The space radiation comes from three major sources including galactic cosmic rays, sun 
radiation and Van Allen radiation belts of the Earth.
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linear track. In contrast to X rays, gamma rays, beta-
particles and high energy neutrons, HZE ions have very 
high LET levels. HZE particles, also called “densely 
ionizing radiation” typically deposit a large amount of 
their energy along linear tracks referred to as cores, while 
the remaining energy is deposited radially and uniformly 
by secondary electrons known as Delta-rays. In contrast, 
low-LET particles deposit their energy uniformly and are 
often referred to as “sparsely ionizing radiation”. We have 
previously illustrated the difference of microdosimetry 
profiles between low and high-LET [37], by using the 
example of one 1 GeV/u 56Fe particle traversing an 
hypothetical square cell. In this example, with the size of 
the cell picked so that one Fe track traversal leads to an 
average dose of 1 Gy in the cell, the local dose within 
0.5 μm radially from the track is 26 Gy whereas the rest 
of the cell is only exposed to a uniform dose of 0.17 Gy 
deposited by Delta-rays (Figure 2).
The most problematic type of DNA lesions induced 
by ionizing radiation are DNA double strand breaks 
(DSBs). Both low- and high-LET induce DSBs, but the 
complexity of damage varies with LET. We previously 
reviewed this topic in detail [38]. Briefly, if we accept the 
convention that a “simple DSB” is made of one break on 
each strand within a 10 base-pair region and “complex 
DSB” have at least one additional break between these 
two strand breaks, then roughly 80% of high-LET induced 
DSB are complex against only 20% for low-LET [39, 40]. 
The higher carcinogenic effect for high-LET [9, 41] has 
been explained primarily via the larger amount of complex 
break which hypothetically lead to more unrepairable 
lesions.
RADIATION DNA DAMAGE AND 
MECHANISMS OF REPAIR
All eukaryotic organisms have evolved against 
a backdrop of constant exposure to endogenous and 
exogenous mutagens, and as such have developed robust 
cellular mechanisms for DNA repair and protection against 
DNA damage. The mechanisms of cellular protection 
against DNA damage and mutation and of DNA repair 
can be categorized as immediate and adaptive defense 
mechanisms.
Immediate defense mechanisms include:
•  The production of antioxidants and reactive 
oxygen species (ROS) scavengers that neutralize 
ROS produced by oxygen metabolism, ionizing 
radiation and UV radiation [42–45].
•  DNA repair [46–49], including direct reversal 
repair, base excision repair (BER) [50–53], 
nucleotide excision repair (NER) [54–56] 
and mismatch repair [57–60] for single strand 
modifications, and non-homologous end-joining 
Figure 2: Comparative diagram on DNA damage induced by Low- and High-LET radiation. HZE particles, also called 
“densely ionizing radiation” typically deposit a large amount of their energy along linear tracks referred to as cores, while the remaining 
energy is deposited radially and uniformly by secondary electrons (i.e. Delta-rays). In contrast, low-LET deposit their energy uniformly and 
are often referred as “sparsely ionizing radiation”.
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(NHEJ), microhomology-mediated end-joining 
(MMEJ), homologous recombination for double 
strand breaks (DSBs), and interstrand crosslink 
repair for modifications affecting both strands 
[61–64];
•  Elimination of damaged cells via apoptosis [65–
68] [69, 70], and
•  Proliferative arrest and replicative senescence 
[71, 72] [73–76]
Substantial experimental evidence suggests that 
low-dose radiation may trigger a variety of protective 
responses within cells, tissues and organisms that 
serve to protect them from both exogenous (e.g high 
doses of radiation) [77] and endogenous (e.g. age-
related accumulation of DNA damage) [78] genomic 
instabilities [79–81]. Importantly, these responses, 
collectively termed radioadaptive responses or radiation 
hormesis, may protect against spontaneous or induced 
cancer [82]. Since radiation-induced tumorigenesis is a 
major risk concomitant with long-distance space travel, 
radiation hormesis has posed serious questions on the 
adequacy and scientific justification of the international 
radiation protection standards [80]. They dictate that any, 
however small, exposure to ionizing radiation leads to 
a proportional increase in cancer risk, thus postulating 
that there are no safe levels of radiation exposure. This 
system is based on the Linear-No-Threshold model that 
extrapolates human atomic bomb survival data obtained 
for high-to-low doses [83]. It appears that low-dose 
radiation-induced protective mechanisms are not specific 
to a certain molecular or cellular pathway and cover a 
broad range of cell-autonomous (DNA repair, anti-oxidant, 
pro-survival gene activation) and non-cell-autonomous 
mechanisms (immune system activation, bystander effects, 
etc.).
In relation to space, it is important to understand 
how radioadaptive responses can be elicited upon 
exposure to high LET radiation types. Early radioadaptive 
response studies failed to demonstrate beneficial 
biological responses upon exposure to low doses of 
high LET radiation [84]. However, more recently such a 
possibility has been demonstrated using human cell lines. 
Not only low-dose X-ray exposure was shown to trigger 
better DNA repair and cause lower mutation frequencies 
in response to high doses of high-LET ion irradiation [85], 
but also low doses of high-LET irradiation were reported 
to produce radiation adaptive responses upon high doses 
of the same high-LET irradiation [86]. Rithidech and 
Scott [87] proposed that the protective mechanisms 
could be triggered in cells by a gamma-component that is 
produced within a body upon exposure to neutrons [88]. 
Additionally, it has been shown that low doses of low 
LET radiation may render resistance to genotoxicity and 
teratogenesis induced by high doses of HZE particles [85, 
89]. Intriguingly, priming normal human cells with low 
doses of energetic protons resulted in lower chromosomal 
damage induced by subsequent exposure to iron ions [90]. 
All of these scenarios are relevant to radiation exposures 
experienced by human astronauts onboard of a spacecraft, 
making it thus conceivable that cells and tissues may be 
made resistant to detrimental effects of GSR by priming or 
ongoing exposures to low LET radiation.
Genome instability resulting from DNA damage and 
mutation in both nuclear DNA and mitochondrial DNA 
caused by replication errors and exposure to endogenous 
and exogenous mutagens has long been implicated as one 
of the main causes of aging [91–96]. All of the above 
strategies for enhancing radioresistance in humans, from 
the expression and overexpression of exogenous and 
endogenous DNA repair genes, antioxidants and ROS 
scavengers, to the expression of exogenous radioprotective 
genes (e.g. Dsup), would also ancillarily serve as a 
means of attenuating DNA damage and mutation caused 
by exposure to the many endogenous and exogenous 
mutagens, foremost among these being endogenous 
ROS produced via normative cellular respiration, that 
are implicated in eukaryotic aging. As such, the above 
strategies for enhancing radioresistance in humans would 
also constitute a promising geroprotective strategy and a 
means of attenuating aging and promoting longevity and 
extension of both lifespan and healthspan in humans as 
well.
In addition to the direct effect of radiation on the 
target cells, a so-called bystander effect has been described 
where nearby, but unirradiated, cells activate their DNA 
damage response [97, 98]. These non-targeted effects 
are underlain by various mechanisms, for instance, at a 
systemic level via the microenvironment and TGF-beta 
signaling [99], via extracellular vesicles (EV), natural 
nanoparticles secreted by different cells and carrying 
protein markers, peptides, mRNA, microRNA (miRNA), 
non-coding RNA (ncRNA), DNA, and retrotransposon 
elements involved in cell-cell communication. Recently 
miRNAs have been shown to play an important role in 
radiation induced bystander effects [100]. Not only can 
miRNAs be contained in EV, but also can be free floating 
throughout the circulation. One study has shown that these 
circulating miRNAs contribute to non-targeted effects by 
traveling between irradiated and nonirradiated cells and 
increase the cells radioresistance [101].
In some studies, specific EV are secreted after 
irradiation, in particular, after radiation therapy. 
Experiments on cell cultures have demonstrated that 
EV and probably mRNA present in these EV mediate 
the development of the bystander effect [102–104]. In 
addition, a direct correlation between the amount of 
EV and irradiation dose has been demonstrated [105]. 
In experiments performed by Jella KK et al., exosomes 
(particles sized 30-100 nm) and microvesicles (>100 
nm) were isolated after cell exposure to radiation in 
different doses and their concentration depended on the 
irradiation dose [103]. In vitro experiments have shown 
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that radiation-induced EV are easily absorbed by cells 
during co-culturing and due to some modifications in 
their molecular composition promote cell migration by 
enhancing activation of TrkA and FAK signaling.
At the organism level, EV act as long-distance 
transport modules capable of crossing the blood-brain 
barrier [106]. EV also play an important role in the 
development of tumor process. Specific EV were isolated 
for human breast epithelial cancer, prostatic cancer, 
glioblastoma, pancreatic cancer, melanoma, and stomach 
cancer [102, 107–110].
When evaluating the effect of space flight 
factors, quantitative and qualitative characteristics of 
microparticles produced by different cells under normal 
and pathological conditions should be taken into account, 
as they considerably influence the development of genetic 
instability, apoptosis, and tumor process. They can provide 
valuable information about the pathological process and 
serve as markers of the corresponding diseases.
MAJOR HEALTH THREAT FROM 
COSMIC RADIATION
Injury to the central nervous system
Space flight conditions (SFC) significantly affect 
the operating activity of astronauts during deep space 
missions [111–113]. Ionizing radiation, especially GCR 
creates a risk for the normal functioning of the central 
nervous system, with acute and chronic exposure leading 
to alterations in the cognitive abilities, reduction of motor 
functions and behavioral changes [114]. In contrast 
to orbital flights, leaving the Earth’s magnetic field 
drastically increases the exposure to ionizing radiation 
(IR) and, above all, high-energy nuclei component of 
cosmic rays (HZE). Thus, during a 3-year-long mission to 
Mars, 13% of neurons in the central nervous system (CNS) 
will be permeated at least once by an iron ion, while at 
the same time, ~ 50% of neurons in the hippocampus 
will be permeated by charged particles with an atomic 
number greater than 15 [115]. There are a lot of disparate 
data about the detrimental effects of the SFC onto the 
cognitive abilities, and on the mechanisms underlying 
neurodegenerative disorders [116, 117]. To date, the 
neurochemical and molecular mechanisms underlying the 
cognitive impairments resulting from the effects of SFC 
are not clearly understood; even information about the 
potential risks for the CNS is contradictory [118, 119].
The most harmful component of GCR is the 
HZE particles, e.g. 56Fe. In rodent models, exposure 
to even small doses of 56Fe ions, was shown to induce 
pronounced deficits in hippocampus-dependent learning 
and memory. In particular, a sharp decrease in spatial 
memory and orientation in the Morris water maze and 
Barnes maze were observed after exposure to 56Fe ions 
in doses 0.1-1 Gy [120] [121] [122] [123] [124]. Current 
estimates place the relative biological effectiveness (RBE) 
for 1 GeV/u 56Fe particle-induced hippocampal memory 
impairment at around 50 [120]. Acute exposures of 48Ti 
ions in doses 0.02-0.2 Gy (1 Gev/n) significantly reduced 
the mean spatial memory of the rats at three months after 
exposure, and significantly increased the percentage 
of rats with severe impairment, which manifested itself 
in subpar performance [125]. Indeed, 7, 11 and even 15 
months following exposure to 56Fe ions in doses 1-2 
Gy, the irradiated groups fared significantly worse on the 
ascending fixed-ratio operant task (bar pressing for food 
reward) than the controls.
Rats exposed to proton doses of less than 3 Gy 
suffered disturbances in conditioned taste aversion 3 
days following exposure [126] while doses of 3-4 Gy 
produced transient direct deficits in open field exploratory 
behaviour, acoustic startle habituation and rotarod 
performance in mice [127]. In a rat model, irradiation 
with high-energy protons in doses of 1-2 Gy induced a 
decrease in the efficacy of test performance in T-maze. 
The treatment caused a decrease in the concentration 
of catecholamines in the prefrontal cortex and 3-MT, a 
metabolite of dopamine, in striatum [128].
Exposure to 1 Gy of 12C ions drastically reduced 
the content of 3-MT, 3,4-dihydroxyphenylacetic acid, 
5-hydroxyindoleacetic acid and serotonin in the prefrontal 
cortex of rats [129]. This indicates that the prefrontal 
cortex is the most sensitive area of the brain in terms of the 
deleterious effects of HZE on the content of monoamines. 
Worth mentioning, the changes in the content of 
neurotransmitters regions rich in dopaminergic neurons, 
directly affect the emotional and motivational behavior, 
attention, spatial learning and contextual memory 
[130] [131] [132]. Finally, HZE can induce the strong 
disturbances in the CNS, especially in spatial memory 
and orientation. These disturbances may be critical 
for performance of astronauts in deep space missions. 
The non-radiation SFC, especially microgravity, can 
significantly change the effect of IR injury. Surprisingly, 
the SFC applied in combination may antagonize each 
other, for instance, IR eliminated the cognitive deficits 
occurring in response to the AS. The need for future 
experiments to further investigate this effect and its 
mechanisms is evident.
Cardiovascular diseases
The impact of prolonged exposure to microgravity 
on cardiovascular system has been well characterized. 
Tachycardia, baroreflex dysfunction, and reduced 
physical capacity were observed in experimental animals 
as soon as in 14 days after microgravity modeling [133]; 
[134]. Similar changes were observed in humans under 
conditions of modeled microgravity or after space missions 
[135]. Long-term sympathovagal imbalance increases 
the risk of fatal arrhythmias [136] and is the negative 
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risk factor in cardiovascular disturbances and strokes 
[137] [138]. In astronauts, arrhythmia episodes were 
recorded during performance under stress [139]. NASA 
has recently reported increased cardiovascular mortality 
among lunar astronauts [140]. The authors attribute the 
observed phenomenon to the effect of lunar radiation on 
the endothelium. However, a recent report by Cucinotta et 
al suggests that such conclusions should be revisited due 
to methodological deficiencies in the analyses by Delp et 
al. and that circulatory disease due to space radiation does 
not contribute to mortality in astronauts [141].
Immune effects
Given that the organs of the immune system, 
including bone marrow and lymph nodes are some of the 
most radiation-sensitive tissues in the human body [18], 
it is of little wonder that abnormalities in the functioning 
of the immune system have been observed in astronauts 
as early as the 1970s [142]. In this regard, a depressed 
immune system in astronauts can potentially increase the 
incidence of infection, acute and chronic inflammation, 
and potentially carcinogenesis, while an enhanced immune 
response is associated with allergies and autoimmune 
diseases [143] [144]. Therefore, in combination with the 
greater virulence of pathogens in space [145], immune 
system dysfunction is of major concern for the expansion 
of human presence beyond Earth’s orbit [146].
The human data on the precise impact of cosmic 
radiation on the immune system is lacking, mostly due 
to the fact that there have not been enough manned 
missions outside of the Earth’s magnetic field. In vitro 
investigations show that the d0 (the mean lethal dose) 
values for various lymphocyte lineages range from 0.25-
0.35 Gy [147]; by comparison, an average for mammalian 
oxygenated cells is around 1.5 Gy. Simulated cosmic 
radiation experiments performed on lymphocytes also 
indicate extensive chromosomal exchanges as a result 
of irradiation, the impact of which can be somewhat 
mitigated by shielding [148].
Data from animal model experiments performed 
on Earth is in accord with the above: in a rat experiment, 
whole-body 1 Gy irradiation produced an acute decrease 
in the concentration of circulating lymphocytes [149]. 
Subsequent experiments simulating galactic cosmic 
irradiation and solar particle events on mice demonstrated 
both chronic and acute deleterious effects on lymphocyte 
populations, functioning and chromosomal stability, 
with circulating B lymphocytes being the most affected, 
followed by T-cells and natural killer cells (reviewed in 
[18] and also in [150]).
In the context of radioprotection, previous studies 
investigated whether pre-exposure to radiation might 
have an impact on an individual’s radiation sensitivity 
of the immune system. So far, different studies gave 
contradictory results [151] [152] [153] [154]. Therefore 
it is worthwhile to further investigate whether pre-
exposure to low-dose radiation may offer some degree of 
radioprotection.
Cancer and aging
The concept of DNA being the main target of 
ionizing radiation, combined with the classical views 
of molecular biology that DNA mutations are the main 
initiating and propagating events driving cellular 
neoplastic transformation and carcinogenesis [155], has 
led to the acceptance of the risk of fatal cancer as the 
major health risk of exposure to radiation [22]. Predicting 
such risks and their management is implemented in the 
current international radiological protection system that 
is comprised of a number of international and national 
advisory (e.g. ICRP, UNSCEAR) and regulatory bodies 
(e.g. NCRP, NIOSH, CNSC). Their cancer risk models 
and guidelines are predominantly based on the findings 
of the epidemiological life span study of atomic bomb 
survivors in Japan [156]. Although the exposure doses in 
those human cohorts were high, the derived relationship 
between dose and cancer is extrapolated back to low 
doses to calculate cancer risks encountered upon 
environmental or occupational exposure to low doses. 
This is accomplished with the help of a dose and dose rate 
effectiveness factor – accounting for sparing of the effect 
of chronic low-dose exposures – and a radiation quality 
factor that is based on relative biological effectiveness 
(RBE) of a particular radiation type and is linked to a LET 
value. Since high-LET particles – known for their high 
RBE - are a substantial component of cosmic radiation, 
fatal cancer risks associated with space missions are an 
obvious and a serious concern and limits space mission 
length.
Cancer and aging are intricately related [157]. 
Indeed, aging, as a factor, is the largest contributor to 
cancer [157, 158]. A global view of how age affects the 
host was recently discussed by López-Otin et al. [95] 
categorizing nine “hallmarks of aging” in the host, but 
minimal evidence was included towards the direct impact 
of these hallmarks on cancer progression. Molecular 
factors involved in the hallmarks of aging are impacted by 
the individual organs, which are usually not considered a 
factor in carcinogenesis unless discussing the immediate 
tumor microenvironment [159]. Changes with the immune 
system as a function of age stemming from the spleen 
have potential to affect cancer risk and tumor progression 
[160]. Limited research exists on cancer risk as a 
function of age and sex for the interplay between organs. 
Astronauts typically have an age range of 35-55 years old 
[161] providing potential biological differences in the host 
as a function of age that can impact tumor progression. 
Age and sex are typically studied together obscuring the 
effects of a central determinant on overall cancer risk. 
Understanding how systemic host change as a function of 
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age and HZE irradiation will greatly improve cancer risk 
models for space travel.
In mice, genetic modifications that cause increases 
in lifespan are also able to concurrently reduce cancer 
rates [162] and vice versa [163]. Taken together, the 
model of aging-related accumulation of mutations 
(Lopez-Otin, 2013) and the multistep mutational theory 
of carcinogenesis [164] explain well such a strong 
connection. Although somewhat simplistic and not capable 
to explain some experimental observations (e.g. leveling 
off of cancer incidence at advanced age), this explanation 
may be useful for predicting cancer risks upon exposure 
to radiation since many observations related to aging 
can be used to draw connections to cancer. For example, 
disruption of DNA repair or DNA damage response 
pathways are frequently observed in both aging and cancer 
phenotypes [165, 166]. Since epidemiological studies of 
cancer incidence among astronauts are not practical due 
to low group size and associated low statistical power, 
terrestrial studies examining HZE particles-induced 
changes in various endpoints related to cancer and aging 
are of primary importance for improving cancer risk 
models for cosmic radiation exposures.
Modeling cosmic radiation on Earth is extremely 
difficult due to its very complex particle spectrum and 
the presence of very high energy nuclei. However, 
various laboratories built around large nuclear facilities, 
such as accelerators, have used heavy ions of 56Fe, C, 
He, protons, and some others for studying the effects of 
HZE particles on a range biological endpoints, such as 
cancer, systematic response to radiation induced cancer, 
and DNA damage in both animal and cell culture models 
[167]. In vitro or ex vivo studies offer greater opportunities 
for detailed characterization of RBE as a function of LET 
for various endpoints related to carcinogenesis, such 
as chromosomal aberrations, mutations and neoplastic 
transformation when compared to in vivo studies, but are 
harder to relate the impact on aging. RBE of HZE particles 
for induction of neoplastic transformation in mouse 
C3H10T1/2 cells varied between 2 and 10 depending 
on the LET value of a particular heavy ion [168]. These 
RBE values may have been underestimated due to the 
use of X-rays instead of γ-rays as a reference radiation 
and the use of readouts at 50% cell survival levels. Using 
chromosomal aberration induction in human peripheral 
blood lymphocytes exposed ex vivo to various heavy ions, 
RBE values of 10 and 30 were produced for cycling and 
interphase cells, respectively [169, 170]. Interestingly, 
these studies independently revealed a similar pattern of 
RBE dependence on LET by using varying energies of Si 
nuclei [170] or different nuclei [168], with the maximum 
RBE observed at around 100 keV/μm. Similar RBE were 
shown for HPRT mutations [171].
Although very limited in number, animal studies 
in general show substantially higher cancer rates when 
compared to low-LET radiation exposures. Thus, 
HZE irradiation was 20-40 times more effective in 
inducing Harderian gland tumors in mice compared to 
low-LET irradiation [41, 172]. This effectiveness was 
even increased when a single acute dose was split into 
several fractions, indicating that the attenuation effect 
seen for low-LET radiation at low dose rate exposures 
is not present for HZE nuclei [173, 174]. Similar RBE 
estimates were obtained for skin and mammary tumors 
in rats exposed to Fe nuclei; however, no changes upon 
fractionation were found in RBE values [175–177]. 
Interestingly, Fe particles induced acute myeloid leukemia 
with the same efficiency as 137Cs γ-rays [172], consistent 
with α-particle results in mice [178] and the thorotrast 
patients study [179]. More recently, Miousse et al. [180] 
showed that epigenetic alterations related to genomic 
DNA methylation, rather that accumulation of DNA 
damage, were observed in bone marrow hematopoietic 
stem cells of mice exposed to 56Fe heavy ions. With 
respect to aging, irradiation of fish embryos with 56Fe 
particles, but not γ-rays, lead to increased levels of lipid 
peroxidation products and other oxidative metabolism 
pathology, suggesting a higher potential of HZE ions to 
affect aging when compared to low-LET radiation [181]. 
Lastly, studies of peripheral blood lymphocytes from 
human astronauts flown on various length International 
Space Station missions showed increased levels of 
chromosome aberrations [182] and their stability over time 
indicating higher complexity and carcinogenic potential 
[183]. Overall, in vivo results are consistent with in vitro 
studies and confirm substantially higher capacity of the 
HZE component of cosmic radiation to trigger cancer-
related changes compared to low-LET radiation.
In addition, to the factors mentioned above recently 
miRNAs have been implicated in cancer risk and space 
radiation. MicroRNAs (small non-coding RNA molecules 
with a negative and post-transcriptional regulation on 
gene expression) have recently been implicated in age, 
sex, radiation, and radiation bystander effects. It is known 
that each miRNA can target hundreds of mRNAs, which 
predicts that over half of the existing human transcriptome 
is regulated by miRNAs [184, 185]. A bystander response 
to low-LET radiation has been shown to have a sex-
specific deregulation on miRNA signature in non-exposed 
spleens [186]. Evidence also suggests a tissue-specific 
coordinated pool of miRNAs contribute to the “hallmarks 
of aging” [187]. These pools of miRNAs are also shown to 
impact both innate and adaptive immune responses, which 
can be altered by cytokine stimulation from such factors as 
TGFβ1 [184, 185, 187]. Recent studies have also started to 
show the importance of certain miRNA signatures driving 
cancer progression [188–191]. Studies involving low-LET 
radiation have demonstrated specific miRNA radiation-
dependent signatures [192], but little is known on the 
potential impact of miRNA and HZE irradiation. Overlap 
exists between the miRNA signatures in various cancers, 
age related miRNAs, and miRNAs associated with low-
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LET radiation, but little is reported on how all these 
factors uniformly impact cancer progression and effect 
cancer risk due to space radiation. Further, the impact of 
where and how the miRNAs affecting these factors (i.e. 
non-tumor related organs) is not understood.
Although cosmic radiation risks include cataracts, 
circulatory disease, damage to CNS and others, risks of 
fatal cancer is the major component and contributor to 
overall radiation health risks that are being estimated 
and used for operation and planning of human space 
missions [193]. Due to the inherent paucity of human 
data on the space radiation effects on cancer and aging, 
and difficulties in recreating space radiation fields in 
the ground-based research studies to better characterize 
biological effectiveness of such radiation for cancer and 
aging related endpoints, current health risk estimates 
carry large uncertainties. It is therefore anticipated that 
cancer and aging will continue to play a dominant role in 
future studies to a) minimize the uncertainties to improve 
health risk management, b) to identify individual factors 
affecting radiation sensitivity and c) to generate sufficient 
knowledge for implementing various biotechnological 
countermeasures described in the next section.
WAYS TO REDUCE HEALTH RISKS 
FROM SPACE RADIATION
The principal scheme of the possible interventions to 
reduce the health risks from space radiation are presented 
in Figure 3.
Medical selection of radioresistant people
Countries actively engaged in development of the 
spaceflight missions, such as United States and Russia, 
have well-established protocols for selection of the 
potential candidates. While these selection pipelines 
differ substantially from one to another [194, 195], in 
vitro adaptive response studies is the only approach widely 
implemented for the medical selection of the radioresistant 
individuals [196, 197]. Nevertheless, according to 
current regulations, the results of such studies are not 
necessarily taken into consideration along the process of 
candidates selection for the spaceflight. There is a strong 
evidence of a wide range of adaptive response among 
different individuals, suggesting that medical selection 
of the candidates based on the in vitro adaptive response 
Figure 3: Ways to reduce health risks from space radiation during deep space travels. Multiple approaches from medical 
selection of radioresistant individuals to gene therapy may be proposed.
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studies is very promising [118, 196, 198, 199]. The wide 
spectrum of responses may be explained by various rates 
of DNA damage accumulation and repair [200–204]. The 
general objective behind such studies is to collect the cell 
samples from the potential candidates (lymphocytes, skin 
fibroblasts, etc.) and using these samples for analysis of 
the adaptive response curves. The implemented readouts 
may include measurement of cell viability, various 
indicators of DNA damage and repair markers (H2AX, 
53BP1, etc.) after the exposure to IR [161, 201, 205–
209]. Moreover, markers specific to the particular DNA 
repair mechanisms (RAD51, Ku70/80, ATM) may be of a 
particular interest, as numerous studies have shown higher 
error-proneness of non-homologous end joining compared 
to the homologous recombination [31, 32, 38, 210–212]. 
Application of the comprehensive multi-omics analytical 
tools on transcriptomic and proteomic data may serve as 
another useful approach for the individual radioresistance 
assessment [213–216]. All the approaches discussed in 
the next chapters, combined with the initial selection of 
radioresistant individuals, should significantly empower 
our ability to protect space mission crew members against 
the HZE-irradiation.
Small molecule-based interventions
Radioprotectors and geroprotectors
Small molecule interventions for radiation 
protection have been studied for many years. Such 
molecules are called radioprotectors. To date, amifostine 
(Ethyol, MedImmune) is still the only FDA approved 
radioprotector for treatment of radiation toxicity [217]. 
Nevertheless, there is still a large potential in this field. 
Particular pathways playing key role in aging-related 
pathologies are also involved into ionizing radiation 
response, for example PI3K/AKT [218], mTOR [219], 
NF-kB [220], p53 and ATM [221], FOXO, JNK and 
SIRT1 [222], ERK [223], JMJD3 [224], TGFb [225]. 
In other words, ionizing radiation causes accelerated 
aging both at the cell level (stress-induced premature 
senescence) and in the body [226, 227]. Therefore, it is 
not surprising that some geroprotectors (pharmacological 
agents that decrease the rate of aging and extend 
the lifespan) are able to reduce the damaging effect 
of ionizing radiation, for instance, curcumin [228], 
quercetin, (-)-epicatechin, and ibuprofen [229]. At the 
present day, according to Geroprotectors.org (http://
geroprotectors.org/) [230] and DrugAge (http://
genomics.senescence.info/drugs/) [231] databases, there 
are more than 400 potential geroprotectors, compounds 
that prolong model organism’s life span at least in one 
concentration [232] (Figure 4). The drug repurposing 
approach may be very useful in search for the new radio- 
and geroprotectors [233].
The role of redox scavengers in radioprotection
Glutathione (GSH) is a tri-peptide redox scavenger 
abundant in eukaryotic cells. Its capacity to prevent 
oxidative damage rests in the presence of a cysteine 
residue in both it and its cognate disulfide (GSSG). 
More specifically, the thiol group readily participates in 
radical chemistry, enabling it to nullify the deleterious 
effects of ROS. Indeed, in vitro assays show that GSH 
at concentrations of 100 μM (with the physiological 
concentrations being in the mM range) was capable of 
protecting equimolar nucleic acids from γ radiation-
induced degradation, even at doses reaching 400 Gy 
[234]. On a cellular level, it has been known for a long 
time that exogenous supply of glutathione can serve as a 
radioprotectant – lymphoid cell lines subjected to GSH 
depletion exhibit radiosensitivity to 7 Gy of γ radiation, 
which is rescued by GSH repletion [235]. In addition, 
GSH can serve as a useful biomarker of cellular oxidative 
stress and aging; in a rat model, young specimens had 
significantly higher levels of intracellular GSH, which 
correlated negatively with the extent of DNA damage 
[236]. There is evidence that the radioprotective properties 
of glutathione can be exploited therapeutically. For 
example, diselenonicotinamide (DSNA) is a synthetic 
organometallic compound, the administration of which in 
a cellular context protected Chinese Hamster Ovary and 
murine splenic lymphocyte cells from radiation-induced 
cell death at doses of 25 μM administered before and even 
after the irradiation of 1-12 Gy [237]. Another compound, 
silymarin, when administered orally for 3 days in a 
mouse model resulted in a 67% survival rate after 30 days 
following lethal 9 Gy γ irradiation, with a concomitant 
increase in the activity of enzymes participating in the 
GSH pathway [238].
The coenzyme nicotinamide adenine dinucleotide 
(NAD) and its cognate reduced form, NADH, is a 
reducing equivalents carrier known for participating 
in various metabolic reactions paramount to cellular 
respiration. Whilst originally thought of mostly as a 
metabolic ancillary, evidence has emerged of it being 
an important indicator of the redox state of the cell, and 
concomitantly, a factor in aging and tissue regeneration. 
Early reports at the turn of the decade suggested that 
NAD levels are negatively impacted by high-fat diet and 
linked to type 2 diabetes (T2D), with NMN (a precursor 
to NAD) supplementation being capable of improving 
insulin sensitivity and glucose tolerance in a mouse model 
of T2D [239]. Strikingly, NAD levels were shown to 
decrease with age, and along with them the activation of a 
histone deacetylase family of proteins, known as Sirtuins 
(SIRT1-7). Sirtuins, responsible for the regulation of gene 
silencing, use NAD as a cofactor and also happen to be 
involved in aging and disease. For instance, one of the 
targets of SIRT2 is a mitotic checkpoint kinase BubR1, 
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the levels of which have been associated with longevity. 
In a mouse model, the age-related decline in BubR1 levels 
was predicated upon the decline in NAD levels and vice 
versa: overexpression of SIRT2 or administration of NMN 
increased BubR1 levels [240]. Furthermore, it was later 
shown that NMN was capable of ameliorating some of the 
more deleterious effects of aging in a mouse model, with a 
12-month-long trial demonstrating NMN’s positive effects 
on metabolism and physical fitness, as well as vision 
[241]. The recent work from the Sinclair lab at Harvard 
Medical School further establishes the link between NAD 
and aging by supplementing it with their research on DNA 
damage. PARP1, a protein heavily involved in ssDNA 
damage repair, also uses NAD as a cofactor. Interestingly, 
PARP1 gets sequestered and inactivated by a protein 
called DBC1, which incidentally also happens to inactivate 
SIRT1. This led to the hypothesis that elevating NAD 
levels by administering NMN will lead to a decrease in 
PARP1 inactivation by DBC1, leading to an increase in the 
rate of DNA repair. A number of observations confirmed 
this, most notably the fact that older mice tended to have 
lower hepatic NAD concentrations and higher amounts of 
the PARP1-DBC1 complex, both of which were improved 
by NMN [242, 243]. The key region in DBC1 responsible 
for PARP1 sequestration appears to the Nudix Homology 
Domain (NHD), which is present in a large number of 
proteins involved in DNA repair [244]. Thus, NAD and 
its precursor NMN appear to be key regulators of protein-
protein interactions and DNA damage response networks, 
and as such NMN supplementation needs to be taken 
seriously as a possible branch of radioresistance.
Hypostasis, hypothermia and biobanking
Soon after the launch of the first human space 
missions, the lead designer of the Soviet space program, 
Sergei Korolev, has began to develop an ambitious 
project of a manned flight to Mars. His idea was to put 
the crew into a hibernation state during lengthy space 
travel. Although a member of the Soviet Academy of 
Sciences, Vasiliy Parin, has termed this hypothetical 
process as ‘hypobiosis’ [245], the more currently used 
term, ‘hypostasis’, which more accurately reflects this 
physiological process, since the desired hibernation state 
requires not only a decrease of the metabolic rate, as we 
will describe later, but also the slowdown of all vital 
bodily processes down to a complete standstill (stasis), 
with the possibility of subsequent recovery [246]. The 
development of a hypostatic state (HS) is based on the 
repression of complexes III and IV of the mitochondrial 
respiratory chain and transition of the warm-blooded 
organism into the bioenergy of cold-blooded animals 
(i.e. bioenergetics of glycolysis and the Krebs cycle). 
Figure 4: Common molecular mechanisms involved in the response to the effects of space radiation and the 
geroprotectors affecting the regulation of those. Space radiation induces cellular response through the direct DNA damage, ROS 
accumulation and non-targeted effects. These types of damage provoke distinct signalling mechanisms that may be regulated by the small 
molecules.
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The extensive experimental work on the laboratory 
animals which attempted to generate the HS at different 
temperatures, various durations and degrees of depth, 
has led to surprising discovery that mammals have 
increased resistance to the influence of extreme factors. 
Among others, such factors include the deeper levels of 
hypothermia to 0°C, deadly doses of radiation, a state of 
severe irreversible shock blood loss, hypobaric conditions 
of oxygen deficiency (18 km) and deadly magnitude of the 
overload (up to 50 g) [17]. Although the hypostatic state 
has a potential to greatly reduce, if not fully eliminate, the 
radiation-associated risks, and may have a wide range of 
applications for future deep space missions, at the present 
time, it is quite far from the practical usage and requires 
years of extensive research before it can be applied in 
humans.
On a more futuristic note, departure of humanity 
from Earth to colonize other objects/planets, may 
not be compatible, even with all the biomedical and 
biotechnological advancements of the time, with the long-
term survival of the human population due to radiation 
damage encountered during the spaceflight itself. In 
such case, transportation of a bank of cryopreserved 
germ cells destined to give rise to a new population of 
humans on another planet/object seems to be a reasonable 
alternative. Indeed protecting a bank of frozen cells from 
cosmic radiation physically is obviously more feasible 
than protecting a population of humans. Yet, none of 
the humans presently living on Earth may witness such 
endeavour of our civilization and there is hope that a 
variety of other strategies described here that could make 
human sufficiently radioresistant to withstand multi-year 
exposure to cosmic radiation will eventually succeed 
[247].
Gene therapy for deep space exploration
Overexpression of endogenous and exogenous 
antioxidants
One promising strategy is to overexpress 
endogenous antioxidants via administration and expression 
of their cognate transgenes [248]. A variety of teams have 
reported increased radioresistance following the delivery 
of magnesium superoxide dismutase (MnSOD) transgenes 
in a variety of tissues. MnSOD transgenes have been 
delivered both systemically [249] and in a tissue-specific 
manner [250, 251] using plasmid/liposomal vectors, 
resulting in a substantial reduction in early and late-stage 
irradiation damage.
Note that antioxidants can only protect against 
reactive oxygen species (ROS) primarily produced by 
water radiolysis during exposure to ionizing radiation. As 
such, a fraction of the DNA damage induced by direction 
ionization of DNA cannot be prevented by antioxidants. 
The majority of DSB and SSB generated by low-LET are 
induced by ROS (“indirect effect”) and thus antioxidants 
would be most efficient against low-LET. In contrast, 
the majority of damage for high-LET are due to direct 
ionization of DNA making antioxidants less efficient.
However, constitutive overexpression of 
endogenous antioxidants could detrimentally interfere 
with redox signalling [252]. Additionally, while current 
clinical evidence suggests that dietary antioxidant 
supplementation does not interfere with radiation therapy 
for cancer [252, 253], there is a minimal possibility that 
constitutive overexpression of antioxidants could reduce 
the clinical efficacy of radiation therapy for cancer in the 
event of subsequent carcinogenesis. This may happen 
due to enhanced DNA repair capabilities in cancer cells. 
Constitutive expression would also presumably provide 
anticarcinogenic benefits though prior to carcinogenesis 
due to constant reduction of endogenous ROS. It would 
therefore be prudent to use inducible expression constructs 
(e.g. inducible promoters), so that if carcinogenesis were 
to occur the expression of such endogenous antioxidants 
could be halted by no longer administering the trigger 
stimulus used by the inducible expression system.
Indeed, an even more robust approach would be use 
distinct inducible expression systems, such as the use of 
distinct inducible promoters, on a tissue and organ-specific 
basis. If the same inducible promoter were used to control 
the transcription of endogenous antioxidants in all tissues 
and organs of the body then halting the administration of 
that inducible promoter’s trigger stimulus in the event of 
carcinogenesis would halt the radioprotective benefits 
conferred by antioxidant overexpression in all tissues 
and organs of the body. If, however, distinct inducible 
promoters were used to control antioxidant transcription 
and expression in distinct tissues and organs then halting 
the administration of an inducible promoter’s trigger 
stimulus could be restricted to the tumor’s tissue of 
origin without negating the radioprotective benefits of 
antioxidant overexpression in all other tissues and organs 
using a different inducible promoter.
Overexpression of endogenous and exogenous DNA 
repair genes
Overexpression of human and non-human DNA 
repair proteins in mammalian cells has been previously 
explored as a strategy to enhance the efficiency of 
endogenous DNA repair and to reduce mutagenesis 
and associated carcinogenesis in animal models [254, 
255]. This constitutes an intriguing strategy that could 
be utilized to enhance radioresistance of humans for 
the purposes of deep space exploration. Some instances 
(such as overexpression of O6-alkylguanine DNA 
alkyltransferase and yeast AP endonuclease) have led to 
enhanced protection from endogenous and exogenous 
mutagens, while others (e.g. overexpression of alkyl 
N-purine glycosylase and DNA polymerase β) resulted 
in increased genome instability [254, 255]. Continued 
progress in elucidating which DNA repair proteins result 
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in increased DNA repair capabilities and which do not will 
aid in the eventual determination of which DNA repair 
proteins can be usefully overexpressed for the purposes of 
enhancing radioresistance in humans.
However, as with the case of overexpression 
of endogenous antioxidants, even those DNA repair 
proteins that show largely beneficial effects in terms 
of mutagenesis protection may reduce the clinical 
efficacy of radiation therapy for cancer in the event of 
subsequent carcinogenesis due to enhanced DNA repair 
capabilities in cancer cells when constitutively expressed 
[256], while simultaneously enhancing protection from 
carcinogenesis prior to actual malignant transformation. 
It would therefore also be prudent to use inducible 
expression constructs (e.g. inducible promoters) in the 
case of overexpression of DNA repair genes as well, and 
to explore the possibility of using tissue and organ-specific 
inducible promoters to open up the possibility of halting 
the administration of the inducible promoter’s trigger 
stimulus exclusively in the tumor’s tissue of origin, while 
still maintaining the radioprotective benefits of DNA 
repair gene overexpression in all other tissues and organs.
DNA repair processes have evolved to repair 
isolated endogenous DNA damage. Therefore, cells 
can be overwhelmed with the very unlikely event 
of multiple DSB occurring at the same time in close 
proximity within the nucleus. It has been shown that the 
probability of genomic rearrangements resulting from 
incorrect end joining is higher [257–259]. Movement of 
individual DSB into common repair domains makes such 
genomic rearrangements more likely than previously 
anticipated [37] and such phenomenon has been coined 
“DSB clustering”. Computer models have shown that 
spatiotemporal distribution of DSB is in fact sufficient to 
predict individual cell death probability [260]. In addition, 
DSB clustering is a lot more probable for HZE due to the 
significant proximity of DSBs along particle tracks (see 
Figure 2). As such, one can predict the LET dependence of 
RBE for clonogenic survival by simply taking into account 
the spatiotemporal distribution of DSB and the inherent 
clustering properties of DSB [38, 260–262]. In this model, 
two isolated DSB are less toxic to a cell than two clustered 
DSB and thus shows that DNA repair is not as efficient in 
dealing with HZE-induced DSB. In addition, DSB induces 
complex DSB [263], as discussed in previous section, 
which are poorly repaired by nonhomologous end joining 
(NHEJ), the primary DNA repair mechanism of cell [264]. 
Therefore, DNA repair gene overexpression will be less 
efficient for exposure to HZE compared to low-LET.
As previously discussed in detail [38], chromatin 
density mediates the response to DNA damage. The 
full mechanism by which this happens remains unclear, 
but local chromatin structure appears to play a role. 
Chromatin decondensation around the DSB is believed 
to be an important trigger for ATM dimer dissociation 
and subsequent ATM autophosphorylation and activation 
[261, 262]. We have hypothesized that DSB clustering is 
also modulated by chromatin remodeling and may differ 
depending on the cell cycle [265]. Therefore, the ability 
to modulate the chromatin density is another potential 
direction to infer protection to the cell, with tightly packed 
DNA being better protected and thus more resistant to 
ionizing radiation [266]. Interestingly, high chromatin 
condensation is typically associated with gene silencing 
and lower cell activity, just like hypostatic state leads to a 
full stop in cell activity and radioresistance.
Expression of endogenous and exogenous 
radioprotective transgenes
Another potentially more promising strategy 
involves the delivery and expression of exogenous and 
translational radioprotective transgenes. Many organisms 
(e.g. tardigrades, Deinococcus radiodurans) possess 
remarkable degrees of radioresistance, and if the genes 
and molecular mechanisms conferring such high degrees 
of radioresistance can be elucidated and translated to 
humans via gene therapy then this would constitute a 
much more effective strategy to enhancing radioresistance 
in humans for the purposes of deep space exploration than 
the overexpression of endogenous radioprotective genes, 
which are comparatively limited in their radioprotective 
effect. Tardigrades, for instance, are not only remarkably 
resistance to the damaging effects of irradiation [267, 
268]; but much more remarkably have been shown to 
survive direct exposure to space in low Earth orbit [269].
A nuclear protein thought to aid in protection of 
DNA from the damaging effects of ionizing radiation 
in tardigrades, termed Damage suppressor (Dsup), has 
recently been discovered [270]. This protein co-localizes 
with tardigrade DNA, and has also been shown to co-
localize with nuclear DNA in human cultured HEK293T 
cells. The protein is highly basic, which suggests that 
it may associate with nuclear DNA via electrostatic 
interactions, although the protein’s mode of interaction 
with DNA remains to be comprehensively elucidated. 
To examine the possibility that the association of Dsup 
proteins with nuclear DNA aids in protecting DNA from 
radiation damage, the team stably expressed Dsup using the 
constitutive CAG promoter, and confirmed co-localization 
with nuclear DNA via immunocytochemistry. When the 
HEK293 cells were exposed to 10 Gy of X-ray irradiation 
they found that the transfected cells had roughly half as 
many SSBs than the control group. They also examined 
its effect on the amount of DSBs in the transfected cells 
via a neutral comet assay and via analysis of the number 
of γ-H2AX foci (an indicator of DSBs), and using both 
assays found a 40% reduction in DNA fragmentation in 
the transfected cells compared to the control group. They 
also analyzed cell viability following irradiation, as human 
cells often lose proliferative ability following 3-7 Gy of 
X-ray irradiation, and found that following 4 Gy X-ray 
irradiation the transfected cells had slightly increased 
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viability, a much more normal morphology and higher 
proliferative ability than the irradiated control cells. Thus, 
the delivery and expression of Dsup transgenes in vivo 
represents a promising candidate for potential exogenous 
radioprotective transgenes that would aid in establishing 
enhanced radioresistance in humans for the purpose of 
deep space exploration.
Characterization of the genetic determinants of high 
human radioresistance in conjunction with clinical 
translation via multiplex genetic engineering
Single-nucleotide polymorphisms (SNPs) are 
variations in single nucleotides that occur at specific 
positions within an organism’s genome and that are 
present in an appreciable portion of a population (e.g. 
> 1%). As known from radiation oncology, human 
individuals differ in acute radiosensitivity to high 
therapeutic doses of radiation [271]. This is driven by 
genetic germline variation, 90% of which is expressed 
as SNPs [272]. Limited and inconclusive evidence also 
exists that suggests a link between genetic variance and 
health risks associated with low-dose radiation exposures 
[273] and this issue has been identified as one of the most 
important questions in low-dose radiobiology (EU low-
dose research program DOREMI, http://cordis.europa.
eu/result/rcn/183770_en.html). The SNP profile of a 
given individual characterizes the uniqueness of their 
genome. As such, individual differences in radiosensitivity 
within the human population can be characterized by 
differences in individuals’ SNP profiles and epigenetic 
profiles. This opens the door to one conceivable strategy 
– known as genome-wide association studies or GWAS 
- for determining the SNP and epigenetic profiles of 
individuals highly radioresistant to low-dose radiation: 
performing life-long studies of radiosensitivity in very 
large human cohorts with known radiation exposure 
doses. These exposures could be both environmental in 
areas with high natural background radiation levels [274], 
and occupational, such as InWorks cohorts [275]. One 
could conceivably find populations that have naturally 
been exposed to low-dose radiation, such as airline pilots 
and crews, populations exposed to background radon 
or on top of granite, etc. In this way the genomic and 
epigenetic profiles of individuals highly resistant to low-
dose radiation could be characterized via RNA SEQ and 
genome-wide epigenetic profiling of each individual in 
the cohort. The incidence of cancer (minus the baseline 
natural rate of cancer incidence) and other diseases in 
which irradiation is causally implicated would be tracked 
and associated with individuals’ SNP profiles. In this 
way, the specific SNP profiles of highly radioresistant 
portions of the cohort (i.e. those with the lowest incidence 
of cancer) could be identified, and those SNP variants 
that are shared among the most radioresistant portions of 
the cohort identified via statistical analysis. The result of 
such a large-scale study would be the most likely set of 
candidate SNP variants that confer high radioresistance in 
the human population. This strategy resulted in significant 
advances in understanding a role of genetic variability in 
several diseases and identification of molecular targets 
translatable into clinics [276]. Particularly encouraging is 
the fact that successes have been achieved for complex 
phenotypes – cancer being also a complex multistep 
disease - that are highly polygenic, such as psychiatric 
symptoms and autoimmune diseases [276].
Although the cost of SNP profiling has dropped 
significantly over the past few years and it is conceivable 
to carry out such an SNP study in a large cohort, low 
incidence of cancer due to low-dose radiation exposures 
may limit if not preclude the ability to conduct such 
large-scale SNP studies. Next generation sequencing 
(NGS) technologies may help counter this issue, but at the 
cost of substantially increasing the cost of such studies. 
Additionally, the use NGS as opposed to SNP profiling 
may help identify those rare genetic variants that have a 
role in radiosensitivity but not detectable by SNP profiling. 
Gene-wide association studies (GWAS) would provide 
the best possible association between natural genetic 
variation and radioresistance, and the best available means 
of characterizing the genetic and epigenetic determinants 
of radioresistance and radiosensitivity in the human 
population.
If the specific SNP variants conferring increased 
radioresistance in the human population can be 
characterized, this opens up the possibility of using 
targeted gene editing technologies (e.g. CRISPR/Cas9) 
to replicate those SNP variants in individual humans. 
While the scale involved is clinically unprecedented, 
likely requiring hundreds to thousands of nucleotide 
modifications per genome, and hundreds to thousands of 
modifications per genome per cell unless germline genetic 
engineering were employed, it nonetheless constitutes a 
foreseeable future strategy for enhancing radioresistance 
in humans for the purposes of deep-space exploration.
Generation and characterization of enhanced 
radioresistance via experimental evolution in 
conjunction with clinical translation via multiplex 
genetic engineering
An additional strategy is to employ experimental 
evolution [277] so as to generate populations of model 
organisms or human cells with enhanced radioresistance 
by exposing each generation to high levels of radiation 
and allowing the survivors to breed, followed by the 
characterization of the genetic determinants of the resulting 
enhanced radioresistance phenotype and the subsequent 
clinical translation of such genetic determinants in humans 
via multiplex genetic engineering. As a case study, a team 
led by Michael Cox produced a highly radioresistant 
population of Escherichia coli (i.e. 3-4 orders of 
magnitude more radioresistant to 3000 Gy of IR than the 
originating generation). Of the 69 mutations generated, 
only 3 nucleotide changes in the DNA metabolism genes 
recA, dnaB, and yfjK accounted for the vast majority of the 
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extremophile phenotype, with 4 other mutations providing 
small but measurable contributions to the phenotype [278]. 
By employing this method using model organisms with 
DNA repair pathways conserved in humans, populations 
with extreme radioresistant phenotypes can be generated 
and the genetic determinants underlying the extremophile 
phenotype could be characterized and translated to humans 
using multiplex genetic engineering (e.g. via the CRISPR/
Cas9 system) in a manner similar to that proposed for 
translating natural highly-radioresistant SNP profiles in 
the human population to individual human patients.
Apoptotic & regenerative technologies
The above strategies involve enhancing 
radioresistance in humans. An alternative strategy involves 
employing therapeutic modalities in regenerative medicine 
[279–281] to facilitate the elimination and substitution 
of endogenous cells damaged by cosmic irradiation. 
The present strategy can be subdivided into two distinct 
approaches consisting of random elimination and 
substitution on the one hand and targeted and radiation-
responsive elimination and substitution on the other.
Random elimination and substitution would involve 
ablating and replacing biological systems in a random 
fashion, independent of the level of irradiation damage 
they have acquired, in order to eliminate and replace any 
cells, tissues and organs that may have sustained enough 
irradiation damage to put them at substantial risk for 
carcinogenesis. The scale of elimination and replacement 
could take place on the level of individual cells, tissue 
or organs depending upon the specific modality of 
regenerative medicine employed. For instance, whole 
tissues and organs could be eliminated and replaced via 
the use of engineered tissues and organs, periodically 
according to the calculated rate of damage and consequent 
physiological detriment (i.e. by measuring or estimating 
the amount of cosmic radiation exposure and replacing a 
given tissue or organ once within the period of time it is 
calculated to have experienced enough cosmic radiation 
exposure to result in serious physiological detriment, e.g. 
a high risk of carcinogenesis).
Alternatively, at the level of cells, a recently proposed 
therapeutic modality in regenerative medicine titled Induced 
Cell Turnover (ICT) could be employed to periodically abate 
the endogenous cells constituting an individual’s tissues and 
organs and replace them with either patent-specific or HLA-
matched human pluripotent cells (hPSCs) in a gradual and 
multi-phasic manner [282, 283]. The proposed procedure 
consists of the quantitative and qualitative coordination 
of targeted endogenous cell ablation with hPSC-derived 
exogenous cell administration to mediate partial and 
whole-tissue/whole-organ replacement at the cellular 
level, mediated in a gradual, multi-phasic manner so as to 
minimize the spatiotemporal distribution of ablation and 
replacement for the purpose of maintaining the homeostatic 
(i.e. structural and functional) integrity of tissues and organs 
throughout the course of the procedure. It is distinct from 
normative cell therapies by the quantitative and qualitative 
coordination of endogenous cell ablation with exogenous 
cell administration for the purpose of creating readily-
accessible vacant niches for administered cells to engraft 
and is presumed to increase the engraftment efficacy of 
administered cells.
While the authors originally proposed the 
therapeutic modality as a means of periodically 
attenuating the accumulation of age-related phenotypic 
deviation for the purposes of treating age-related disease, 
it could potentially be employed for the purposes of 
periodically negating acquired irradiation damage in the 
tissues and organs of humans undergoing long-term space 
travel, along timescales and employing ICT rates and 
spatiotemporal distributions that are calculated to facilitate 
the induced turnover (i.e. elimination and replacement) 
of cells at the rate at which they are expected to acquire 
enough irradiation damage to put them at substantial 
risk of malignant transformation [283]. The ultimate 
aim, then, would be to facilitate the induced turnover of 
tissues and organs at least once within the span of time it 
would take to put them at high risk for carcinogenesis as 
a result of acquired cosmic irradiation damage, which is a 
function of the duration and level of exposure to cosmic 
radiation that spacefaring humans undergo. Indeed, such 
a proposal could have positive potential implications as 
a preventative strategy for carcinogenesis in general, 
regardless of exposure to cosmic irradiation. The above 
strategy could also potentially be used to attenuate the 
negative physiological effects of long-term exposure to 
microgravity when specifically targeted to the constitutive 
and supportive cells of muscular and osseous tissues.
The second approach, involving the targeted and 
radiation-responsive elimination and substitution of cells, 
consists of engineering the cells constituting an individual’s 
tissues and organs to undergo apoptosis in response to the 
acquisition of irradiation damage in a targeted fashion, in 
accordance with either the self-detected levels of cosmic 
irradiation they are exposed to or the self-detected amount 
of irradiation damage that they acquire, such that they 
commit apoptosis at levels of acquired irradiation damage 
(e.g. clustered DNA damage) below the levels normatively 
required to induce the endogenous apoptotic response to 
DNA damage. This would most likely consist of the use 
of a radiation-responsive promoter that drives expression 
of a synthetic or a recombinant transcription factor that 
binds very specifically to a synthetic promoter that up-
regulates a pro-apoptotic factor (Figure 5). Such system 
needs to be tuned up such that even slight up-regulation 
of the synthetic transcription factor would lead to a robust 
expression of a pro-apoptotic factor, ensuring elimination 
of a cell damaged by cosmic radiation. Also, this system 
would need to include a trigger for the activation of 
somatic stem cells (SCSs) in the case of renewing tissues 
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and engineered hPSC niches in the case of non-renewing 
tissues so as to replace those endogenous cells that are 
terminated in response to cosmic radiation exposure. 
For instance, the radiation responsive promoter could 
also control the transcription of an endocrine factor, 
activates and/or upregulates SCS or hPSC endogenous 
and/or synthetic or translational factors controlling SCS 
and hPSC proliferation and mobilization in a targeted 
manner (such that each distinct tissue-specific SCS and 
hPSC population is equipped with a specific promoter 
correlating with a distinct synthetic or translational 
endocrine agent). Obviously the technical realization of 
such a genetic regulatory system will require substantial 
effort. However, many elements of it can be suggested 
using present knowledge. For example, radiation-inducible 
promoters have been proposed and optimized for use in 
combination with radiotherapy for cancer and may include 
the egr-1 promoter or its elements [284], a fusion of dCas9 
with multiple copies of the herpes virus transcriptional 
activation domain VP16 guided to the synthetic promoter 
of a pro-apoptotic factor by small guide RNA [285], also 
driven by the radiation-inducible promoter, to ensure its 
specificity and a lack of activation at the basal condition 
(Figure 5).
These considerations, however, need to take account 
of quantitative assessment of the rate of lethal/oncogenic 
cell damage occurring as a result of exposure to cosmic 
radiation. Thus, it was estimated that every cell of a human 
body is traversed by a proton every three days, by a helium 
ion every month and by a HZE particle every 100 years 
[286]. Whereas traversal by a proton may not be lethal 
or mutagenic since only at the end of a track a proton 
would produce a highly compact ionization track, heavier 
particles would definitely produce sufficient damage to 
either kill or produce chromosome damage upon every hit. 
Therefore, it would be ideal if the trigger of cell removal 
would sense the outcome of cell response to a particle 
hit, rather than a hit itself, so that every cell is given an 
opportunity to successfully repair damage. This would 
lead to removal of only those cells that failed to properly 
repair their genomes, helping to maintain the regenerative 
potential of the body or exogenous sources for longer 
periods of time.
One potential limitation of such a system would 
be leakage as a result of its non-linear regulation, and 
as such stringent preliminary studies and trials to as to 
optimize its design for liminal leakage would be required. 
Such an idea is nonetheless presently conceivable and as 
such constitutes a future research strategy that should be 
explored for the purposes of minimizing the effects of 
cosmic irradiation for the purposes of long-term human 
space travel, and could have additional use as a general 
preventative strategy against carcinogenesis via the use 
of both radiation-responsive promoters and carcinogen-
responsive promoters.
Deuterated organic compounds
All organic compounds contain carbon-hydrogen 
(C-H) bonds. It is, however, possible to synthesize 
Figure 5: Conceptual diagram of a genetic system for elimination of radiation-damaged cells and subsequent inducible 
stem cell activation and regeneration of affected tissues. A variety of specific genetic elements that could be used in such system 
have previously been described (see text for further detail).
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organic compounds that have hydrogen atoms replaced 
by deuterium (the stable isotope of hydrogen) at specific 
locations. Due to deuterium’s comparatively greater mass 
with respect to hydrogen, carbon-deuterium bonds require 
more energy to break and take longer to break than C-H 
bonds. Consequently, the energy required to break the 
hydrogen bonds between DNA bases would be greater, and 
deuterated DNA would be less subject SSBs and DSBs 
than non-deuterated DNA. Indeed, the incorporation of 
deuterated water into organisms’ diet has been previously 
explored as a radioprotective strategy, and has been shown 
to increase survival following irradiation by a statistically 
significant extent (e.g. 65% survival compared to 25% in 
the control group following 8.5 Gy irradiation in mice) 
[287].
The extent with which we could deuterate a given 
organism, however, is limited by several potential 
problems. Specifically, the rate at which bonds between 
deuterium and other atoms break is lesser than the rate at 
which bonds between hydrogen and other atoms break due 
to the kinetic isotope effect (a mechanistic phenomenon 
where isotopically substituted molecules react at differing 
rates). Isotopic substitution affects only mass-dependent 
properties (e.g. vibrational frequencies), but has no effect 
on the values of atoms’ electronic states or the potential 
energy surface of a given reaction. Due to the greater mass 
of deuterium with respect to hydrogen, breaking the bonds 
holding various deuterated organic compounds together 
would require more energy, which is a potential problem 
because organisms have evolved in an environment that 
requires only enough energy allocation to break bonds 
between hydrogen and other atoms. In other words, 
organisms are not energetically adapted to catabolize 
organic compounds containing deuterium.
A more pertinent potential problem, however, is 
the fact that the greater mass of deuterium with respect 
to hydrogen implies that the rate of metabolic reactions 
may be slower due to the decreased rate of bond-breaking 
in deuterated organic compounds, which is problematic 
due to the precise coordination and timing of metabolic 
reaction rates that organisms are adapted to and that are 
required to facilitate normative metabolism. It may thus 
be possible to deuterate an organism by a certain amount 
without witnessing significantly detrimental physiological 
effects, but the specific safety threshold would have to be 
determined through a variety of preclinical studies and 
clinical trials.
Moreover, incorporation of isotope-reinforced food 
and water has emerged as a novel means of promoting 
longevity and the maintenance of several aspects of 
health in eukaryotes [288]. Several teams have reported 
that the administration of deuterated water increases 
the lifespan of yeast in a dose-dependent manner by as 
much as 80% [288]. In multicellular eukaryotes, however, 
bodily incorporation of deuterated water above 20% 
begins to have toxic effects. Nonetheless, incorporation 
of deuterated water has been shown to either increase 
longevity or healthspan in yeast, Caenorhabditis elegans, 
Drosophila melanogaster, rodents and humans [289–293], 
and has been found to have anti-cancer effects in rod 
[294–298]ents [299, 300] and humans [301]. Such effects 
are thought to be the result of protection against DNA 
damage and mutation from ROS and exogenous mutagens.
An intriguing alternative involves supplying 
organisms with food containing stable isotopes of 
carbon, e.g. 13C, [302, 303] which has a greater mass 
than 12C (which comprises the majority of natural carbon 
in organisms), but only ~8% greater than 12C, whereas 
deuterium has a mass 100% greater than hydrogen. This 
means that while the rate of bond breaking in the C-H 
bonds of organic compounds having 12C replaced with 
13C would be slower, it may not be so slow as to disrupt 
the timing and coordination of metabolic reactions or to 
significantly affect the necessary energy allocation to 
catabolic reactions required for their ongoing maintenance. 
However, this would only be capable of potentially 
reducing the damaging effect of ionizing radiation for 
organic compounds like proteins, and not DNA because 
the hydrogen bonds occurring between DNA bases are 
N-H and O-H bonds rather than C-H bonds, and the 
problem of irradiation-induced DNA SSBs and DSBs in 
particular are much more detrimental than irradiation-
induced damage to gene products. Furthermore, it is 
currently extremely costly to produce. It may, nonetheless, 
constitute an ancillary strategy for reducing the overall 
damaging effects of radiation to humans as it pertains to 
deep space exploration, provided that a less costly means 
of producing it could be developed.
UTILIZING THE ADVANCES IN 
ARTIFICIAL INTELLIGENCE FOR 
DIAGNOSIS AND TREATMENT OF 
RADIATION- AND AGING-INDUCED 
DAMAGE
In recent years much progress has been made in the 
applications of artificial intelligence and specifically deep 
learning to biomarker development and drug discovery 
[304]. Deep neural networks (DNNs) were applied to 
profiling of the biological samples [305] predict the 
age of a patient using the basic clinical blood tests and 
identify the most important features [306]. Similar 
concepts can be applied to other data types including 
transcriptomic, proteomic, imaging, photographic, 
activity and physiological data to evaluate the minute 
changes transpiring during aging or due to the irradiation 
in space. These minute changes can be addressed with the 
many interventions described in section VI. A prototype 
of such a system for monitoring a variety of data types 
over time called Young. AI was recently launched for 
testing (www.young.ai). Developing comprehensive 
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predictors of age and accumulated damage using multiple 
data types on the population level and re-training them 
on the individual spacefarers is one of the approaches 
to build the artificially-intelligent health monitoring 
systems and assess the types of damage and the resulting 
changes that are difficult to predict with the amount of 
information available before the long-term exposure to 
radiation and a variety of other stress factors in space. 
Space colonists should also have the ability to engage 
in AI-enabled personalized drug discovery and rapid 
validation techniques. On Earth the drug discovery and 
development for a known indication takes many years and 
the likelihood of approval (LOA) of a drug from phase 1 
to the Food and Drug Administration (FDA) approval is 
10.4% for all indications [307]. In space this process must 
be expedited and artificial intelligence can be employed to 
identify the effective molecules from the existing chemical 
space [308] or even generate novel molecular structures 
with the desired set of parameters [309].
CONCLUSION
We have outlined several alternative and 
complementary strategies for enhancing human 
radioresistance for the purposes of deep space 
exploration and colonization using existing biomedical 
and biotechnological tools and modalities in an attempt 
to lay the foundation for a comprehensive roadmap 
towards highly radioresistant humans. While many of 
the strategies proposed above may seem speculative, 
they should be considered as a foundation for future 
research directions. Meanwhile, we have highlighted 
the link between radioresistance and aging, and have 
endeavored to show how many of the biomedical and 
biotechnological modalities discussed in the present review 
could combinatorially be applied to both enhancing human 
radioresistance on the one hand and healthy longevity on 
the other. We also highlighted the need to converge and 
accelerate the research in radiobiology, biogerontology and 
AI to enable spacefarers to address the healthcare challenges 
we may not yet be aware of. Furthermore, given the massive 
amount of funding allocated to research into facilitating and 
optimizing space exploration and optimization, we hope to 
have shown how research into enhancing radioresistance 
for space exploration could galvanize progress in human 
healthspan extension, an area of research that is still 
massively underfunded despite its potential to prevent the 
massive economic burden posed by the future healthcare 
costs associated with demographic aging.
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